{"id":16562,"date":"2012-06-01T10:07:30","date_gmt":"2012-06-01T10:07:30","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=16562"},"modified":"2012-07-21T05:41:54","modified_gmt":"2012-07-21T05:41:54","slug":"warfarin-and-arvs-impact-of-african-american-race-and-ritonavir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/16562","title":{"rendered":"Warfarin and ARVs: impact of African American race and ritonavir"},"content":{"rendered":"<p><strong><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-16567\" title=\"13th PK logo\" src=\"https:\/\/i-base.info\/htb\/files\/2012\/05\/13th-PK-logo.png\" alt=\"\" width=\"160\" height=\"81\" \/>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>The commonly prescribed anticoagulant warfarin is highly susceptible to interactions with antiretroviral mediated through CYP 2C9, 2C19, and\/or 3A4 pathways, although data are limited. <\/strong><\/p>\n<p>This retrospective, case-control (1:2) study compared the warfarin maintenance dose (defined as the dose required to maintain goal INR) between patients on ART (n=18) and patients not on ART (n=36). ART was PI-based (n=9: mainly lopinavir\/r), NNRTI-based (n=7, mainly efavirenz), and PI+NNRTI-based (n=2). The warfarin maintenance dose (mean\u00b1SD) differed significantly between cases and controls (8.6\u00b13.4 mg vs 5.1\u00b11.5 mg, p&lt;0.01), but not across ART regimens (PI: 8.8\u00b14.6 mg; NNRTI: 8.6\u00b11.8 mg; PI+NNRTI: 7.3\u00b13.3 mg; p=0.86).<\/p>\n<p>African American race and ritonavir dose were independent predictors of warfarin dose; with an expected increase by 3.9 mg ([95%CI: 0.88-7.0], p=0.02) if African American or by 3.7 mg ([95%CI: 0.53-6.9], p=0.03) if the total daily ritonavir dose is 200 mg. Higher empiric warfarin doses and\/or more vigilant monitoring and dosage adjustments may be required in these patients.<\/p>\n<p>Reference:<\/p>\n<p>Darin KM et al. The clinical implications of antiretroviral drug interactions with warfarin: a case-control study. 13th PK Workshop, 16-18 April 2012, Barcelona. Abstract: P_18.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base The commonly prescribed anticoagulant warfarin is highly susceptible to interactions with antiretroviral mediated through CYP 2C9, 2C19, and\/or 3A4 pathways, although data are limited. This retrospective, case-control (1:2) study compared the warfarin maintenance dose (defined as &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,34],"tags":[136],"class_list":["post-16562","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-pk-and-drug-interactions","tag-pk-workshop-13th-2012"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/16562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=16562"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/16562\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=16562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=16562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=16562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}